In his weekly clinical update, Dr. Griffin discusses the detection of circulating vaccine-derived poliovirus type 2 in Burundi and the Democratic Republic of the Congo, the novel oral polio vaccine type 2 story, prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction, adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection, correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel, effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths in people with COVID-19, projected COVID-19 mortality reduction from Paxlovid rollout, and SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.

Click arrow to play Download TWiV 994 (26 MB .mp3, 43 min)

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• cVDPV2 detections in Burundi and the DRC (PGEI) 4:52
• Novel oral polio vaccine type 2 story (The Lancet) 6:59
• Prior COVID-19 infection associated with risk of diagnosed erectile dysfunction (IJIR) 8:17
• Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection (BMJ) 13:37
• Protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals (The Lancet) 15:00
• Effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths (The Lancet) 25:30
• Projected COVID-19 mortality reduction from Paxlovid rollout (JAMA)
• SARS-CoV-2 mRNA vaccines decouple anti-viral immunity (Nature) 30:50
• Contribute to our ASTMH fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 994 36:15
• Don’t crush Paxlovid (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update, Dr. Griffin discusses clearance of longstanding, immune-deficiency-associated, vaccine-derived poliovirus infection following remdesivir therapy for chronic SARS-CoV-2 infection, SARS-CoV-2 exposure in New York City rats, clinical characteristics and outcomes of children with SARS-CoV-2 infection during the Delta and Omicron variant-dominant periods in Korea, exhaled breath aerosol shedding of SARS-CoV-2 variants, outpatient treatment of COVID-19 and the development of long COVID over 10 months, Nirmatrelvir and the risk of post-acute sequelae of COVID-19, assessment of the risk of venous thromboembolism in nonhospitalized patients with COVID-19, and the optimal duration of systemic corticosteroids in COVID-19 treatment.

Click arrow to play Download TWiV 992 (19 MB .mp3, 32 min)

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Clearance of vaccine-derived poliovirus following remdesivir therapy for SARS-CoV-2 infection (Frontiers) 1:06
• SARS-CoV-2 exposure in Norway rats from New York City (mBio) 3:28
• Clinical characteristics and outcomes of children with SARS-CoV-2 Infection in Korea (JKMS) 6:54
• Exhaled breath aerosol shedding of SARS-CoV-2 variants (CID) 8:37
• Outpatient treatment of COVID-19 and the development of Long COVID (The Lancet)  12:28
• Nirmatrelvir and the risk of post-acute sequelae of COVID-19 (medRxiv) 16:05
• Risk of venous thromboembolism in nonhospitalized patients with COVID-19 (JAMA) 18:14
• Optimal duration of systemic corticosteroids in COVID-19 treatment (OFID) 21:47
• Contribute to our ASTMH fundraiser at PWB 21:43
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 992 24:40
• Don’t crush Paxlovid (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses confronting the evolution and expansion of anti-vaccine activism in the USA in the COVID-19 era, the effectiveness of maternal Influenza vaccination in Peru, characteristics and predictors of persistent symptoms post-COVID-19 in children and young people, parental nonadherence to health policy recommendations for prevention of COVID-19 transmission among children, community-onset bacterial coinfection in children critically ill with SARS-CoV-2 infection, bivalent booster effectiveness against severe COVID-19 outcomes in Finland, viral kinetics of sequential SARS-CoV-2 infections, risk of COVID-19 associated pulmonary aspergillosis based on corticosteroid duration in intensive care patients, immunomodulators for severe COVID19 in transplant patients: do they increase the risk of secondary infection, long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population, cardiac abnormalities in Long COVID 1-year post-SARS-CoV-2 infection, one-year adverse outcomes among us adults with Post–COVID-19 condition vs those without COVID-19 in a large commercial insurance database, and long-term gastrointestinal outcomes of COVID-19.

Click arrow to play Download TWiV 990 (26 MB .mp3, 43 min) Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Confronting the evolution and expansion of anti-vaccine activism (The Lancet) 1:17
• Effectiveness of maternal influenza vaccination in Peru (OFID) 2:14
• Characteristics and predictors of persistent symptoms post-COVID-19 (BMJ) 4:11
• Parental nonadherence to health policy recommendations for prevention of COVID-19 (JAMA) 6:11
• Community-onset bacterial coinfection in children ill with SARS-CoV-2 infection (OFID) 7:47
• Bivalent booster effectiveness against severe COVID-19 outcomes (medRxiv) 9:56
• Viral kinetics of sequential SARS-CoV-2 infections (medRxiv) 10:46
• Risk of COVID-19 associated pulmonary aspergillosis based on corticosteroid duration in ICU patients (OFID) 13:50
• Immunomodulators for severe COVID-19 in transplant patients (TID) 15:37
• Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population (eClinicalMedicine) 17:00
• Cardiac abnormalities in Long COVID 1-year post-SARS-CoV-2 infection (BMJ) 18:54
• One year adverse outcomes among US adults with post COVID-19 condition vs those without COVID-19 (JAMA) 19:33
• Long-term gastrointestinal outcomes of COVID-19 (Nature) 21:04
• Contribute to our ASTMH fundraiser at PWB 22:19
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 990 22:51
• Don’t crush Paxlovid (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses FDA authorizing the first over-the-counter at-home test to detect both influenza and COVID-19, monoclonal antibody for the prevention of respiratory syncytial virus infection in infants and children, epidemiologic characteristics of SARS-CoV-2 recombinant variant XBB.1.5, COVID-19 vaccines vs pediatric hospitalization, maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life, immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children, fatal fulminant cerebral edema in six children with SARS-CoV-2 Omicron BA.2 infection in Taiwan, certifying deaths due to COVID-19, efficacy of first dose of COVID-19 vaccine vs no vaccination on symptoms of patients with long COVID, and the effect of COVID-19 vaccination on long COVID.

Click arrow to play Download TWiV 988 (26 MB .mp3, 43 min) Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• FDA authorizes over-the-counter at-home test to detect both Influenza and COVID-19 (FDA) 3:07
• Monoclonal antibody for the prevention of RSV in infants and children (JAMA) 8:06
• Epidemiologic characteristics of SARS-CoV-2 variant XBB.1.5 (CDC) 15:13
• COVID-19 vaccines vs pediatric hospitalization (Cell) 17:56
• Maternal SARS-CoV-2 vaccination and infant protection during the first six months of life (Nature) 18:15
• Immunoglobulin, glucocorticoid, or combination therapy for MIS in children (The Lancet) 20:21
• Fatal Fulminant Cerebral Edema in children with SARS-CoV-2 Omicron BA.2 infection (JPID) 21:22
• Certifying deaths due to COVID-19 (CDC) 29:02
• Efficacy of first dose of COVID-19 vaccine vs no vaccination on patients with Long COVID (BMJ) 29:55
• Effect of COVID-19 vaccination on long COVID (BMJ) 30:08
• Contribute to our ASTMH fundraiser at PWB 30:55
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 988 31:43
• Don’t crush Paxlovid (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In his weekly clinical update Dr. Griffin discusses the efficacy and safety of two RSV vaccines in older adults, health care vaccine mandate remains as some push for an end, past SARS-CoV-2 infection protection against re-infection, a third vaccine dose equalizes the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model, effect of higher-dose Ivermectin for 6 Days vs placebo on time to sustained recovery in outpatients with COVID-19, viral burden rebound in hospitalized patients with COVID-19 receiving oral antivirals in Hong Kong, serological response to vaccination in post-acute sequelae of COVID, sex differences in cardiovascular complications and mortality in hospital patients with COVID-19, association of COVID-19 vaccination with risk for incident diabetes after COVID-19, postacute sequelae of SARS-CoV-2 in university setting, the CDC’s long-Covid deception, and podcast companies, once walking on air, feel the strain of gravity.

Click arrow to play
Download TWiV 986 (26 MB .mp3, 43 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• RSV prefusion F protein vaccine in older adults (NEJM) 1:19
• Efficacy and safety of an Ad26.RSV.preF–RSV preF protein vaccine (NEJM) 5:38
• Health care vaccine mandate remains as some push for an end (AP) 8:21
• Past SARS-CoV-2 infection protection against re-infection (The Lancet) 10:51
• A third vaccine dose equalizes the levels of effectiveness and immunogenicity of COVID-19 vaccine regimens (medRxiv) 16:26
• Sotrovimab retains activity against SARS-CoV-2 Omicron variant in primate model (bioRxiv) 18:38
• Effect of higher-dose Ivermectin for 6 days vs placebo in patients with COVID-19 (JAMA) 21:43
• Viral burden rebound in patients with COVID-19 receiving oral antivirals (The Lancet) 
• Serological response to vaccination in post-acute sequelae of COVID (BMC) 26:05
• Sex differences in cardiovascular complications and mortality in patients with COVID-19 (BMI) 27:21
• Association of COVID-19 vaccination with risk for incident diabetes after COVID-19 (JAMA) 28:13
• Postacute sequelae of SARS-CoV-2 in university setting (CDC) 30:00
• The CDC’s Long-Covid deception (WSJ) 33:52
• Podcast companies, once walking on air, feel the strain of gravity (NYT) 35:34
• Contribute to our ASTMH fundraiser at PWB 36:11
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 986 36:40
• Don’t crush Paxlovid (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv